CAS 159519-65-0
:Enfuvirtide
- T-2
- Enfuvirtide(T-20)
- Enfurvitide(T-20)
- Pentafuside
- Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH{2}
- 1-{[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-(butan-2-yl)-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyl-N~5~-(diaminomethylidene)ornithylglycinamide
- Enfuvirtide Acetate
Enfuvirtide
CAS :Enfuvirtide is a 36 amino acid peptide corresponding to a region of gp41, the transmembrane subunit of HIV-1 envelope protein. It belongs to the therapeutic class of fusion inhibitors and acts by binding to gp41 and impeding the conformational changes in gp41 necessary for fusion of the virus with the cell.Formule :C204H301N51O64Degré de pureté :≥ 94%Couleur et forme :White PowderMasse moléculaire :4491.94L-Phenylalaninamide,N-acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl-L-leucyl-L-isoleucyl-L-a-glutamyl-L-a-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-a-glutamyl-L-lysyl-L-asparaginyl-L-a-glutamyl-L-glutaminyl-L-a-glutamyl-L-leucyl-L-leucyl-L-a-glutamyl-L-leucyl-L-a-aspart
CAS :Formule :C204H301N51O64Degré de pureté :99%Couleur et forme :SolidMasse moléculaire :4491.8760Enfuvirtide T-20
CAS :Enfuvirtide T-20Degré de pureté :>97.0% as determined by (Typical Value in Batch COA)Couleur et forme :White Lyophilised PowderMasse moléculaire :4,491.88g/molEnfuvirtide
CAS :Enfuvirtide is an anti-HIV-1 fusion peptide that inhibits HIV p24 antigen and Gag gene expression in macrophages.Formule :C204H301N51O64Degré de pureté :98%Couleur et forme :White To Off-White Amorphous SolidMasse moléculaire :4491.95Enfuvirtide
CAS :Formule :C204H301N51O64Degré de pureté :95%~99%Couleur et forme :White to Off-white PowderMasse moléculaire :4491.88Enfuvirtide
CAS :TFA salt. Enfuviritide is a bicyclic heterocycle that is used in the treatment of HIV/AIDS. It binds to the HIV-1 envelope protein, preventing it from binding to CD4+ cells and infecting them. Enfuviritide has been shown to be effective at increasing the levels of active antiretroviral therapy and has shown significant cytotoxicity against HIV-1 and other infectious viruses. This drug also inhibits viral life by binding to the viral envelope protein gp120 and preventing it from binding to CD4+ cells. However, this drug may have long-term toxicity and may cause drug interactions with other drugs that are metabolized by cytochrome P450 enzymes. Enfuviritide has inhibitory properties against a wide range of antimicrobial agents including Gram-positive bacteria, Gram-negative bacteria, fungi, protozoa, and enveloped viruses.
Formule :C204H301N51O64Degré de pureté :Min. 95%Masse moléculaire :4,491.98 g/mol





